%0 Journal Article
%T Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
%A Economopoulou, Panagiota
%A Kotsantis, Ioannis
%A Psyrri, Amanda
%J AME Clinical Trials Review
%D 2024
%B 2024
%9 
%! Is osimertinib effective as 2nd line treatment in T790M-negative EGFR mutant NSCLC?
%K 
%X 
%U https://actr.amegroups.org/article/view/9137
%V 2
%P 
%@ 3005-6152